Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 17/20 | 0.41 |
| ▸ | GCGR | P47871 | 3/20 | 0.41 |
| ▸ | GIPR | P48546 | 2/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652858 | 0.85 | EPHX2 (0.41) | GCGGCGRGIPRGLP1REGLN2 | |
| SCHEMBL2652354 | 0.80 | GCG (0.46) | GCGGCGRGIPRGLP1R | |
| SCHEMBL2651734 | 0.80 | GCG (0.46) | GCGGCGRGIPRGLP1R | |
| SCHEMBL2666012 | 0.80 | GCGR (0.52) | GCGRGIPRGLP1R | |
| SCHEMBL2653374 | 0.79 | GCGR (0.52) | GCGRGIPRGLP1R | |
| SCHEMBL2653378 | 0.79 | GCGR (0.52) | GCGRGIPRGLP1R | |
| SCHEMBL2650367 | 0.78 | GCG (0.45) | GCGGCGRGIPRGLP1R | |
| SCHEMBL2651267 | 0.78 | GCG (0.43) | GCGGCGRGIPRGLP1R | |
| SCHEMBL2650335 | 0.78 | EPHX2 (0.46) | GCGGCGRGIPRGLP1R | |
| SCHEMBL6750361 | 0.78 | GCG (0.43) | GCGGCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCG 6/4885GCGR 3/4885GIPR 4/4885 |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCG 6/4885GCGR 3/4885GIPR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.